These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25811346)

  • 1. Emerging immunotherapies for bladder cancer.
    Kim JW; Tomita Y; Trepel J; Apolo AB
    Curr Opin Oncol; 2015 May; 27(3):191-200. PubMed ID: 25811346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
    Rassy E; Assi T; Kattan J
    Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
    Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
    J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
    Zibelman M; Ramamurthy C; Plimack ER
    Urol Oncol; 2016 Dec; 34(12):538-547. PubMed ID: 27888981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update 2016 - Immunotherapy for urothelial carcinoma].
    Retz M; Gschwend JE; Schmid SC
    Urologe A; 2016 Feb; 55(2):246-52. PubMed ID: 26767648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
    Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
    Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
    Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
    Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avelumab for the treatment of urothelial cancer.
    Rodriguez-Vida A; Bellmunt J
    Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CRITERIA FOR SELECTION OF TUMOR CELLS AND PROSPECTS FOR SPECIFIC IMMUNOTHERAPY FOR BLADDER CANCER].
    Slavyanskaya T; -Salnikova S; Sepiashvili R
    Georgian Med News; 2017 May; (266):26-34. PubMed ID: 28628011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
    Koshkin VS; Grivas P
    Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
    Yu SS; Dorff TB; Ballas LK; Sadeghi S; Skinner EC; Quinn DI
    Clin Adv Hematol Oncol; 2017 Jun; 15(6):466-477. PubMed ID: 28749907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.